Allogene Therapeutics, Inc.

Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease. Its core idea is to create “off-the-shelf” CAR T products derived from healthy donors, so treatment can be delivered faster and at larger scale than autologous cell therapies made from a patient’s own cells. The company’s pipeline is still in development, with management highlighting upcoming clinical readouts expected in 2026 as potential validation points for the platform. Allogene is focused on a small number of lead programs, including cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease, while also maintaining collaborations that support its gene-editing and biomarker strategy.

−100,0 %

7.93

7.93

— Allogene Therapeutics, Inc.
%
Allogeneic CAR T oncology programs70% Engineered T cell therapies designed to target hematologic cancers such as large B-cell lymphoma and other blood cancers.
Autoimmune disease cell therapy programs20% Allogeneic T cell candidates intended to eliminate pathogenic autoreactive cells in autoimmune disorders.
Platform and gene-editing collaborations10% Licensing and technology partnerships that support next-generation cell engineering and development.

Allogene does not sell commercial products today; its current “customers” are primarily clinical trial participants,...

  • Oncology trial patientsprimary

    Patients with hematologic malignancies, especially large B-cell lymphoma, enrolled to test cema-cel and related allogeneic CAR T candidates.

  • Autoimmune disease patientsprimary

    Patients with autoimmune disorders targeted by ALLO-329 and other next-generation CD19 programs to reduce pathogenic autoreactive cells.

  • Clinical trial sites and investigatorssecondary

    Hospitals, cancer centers, and research sites that administer the company’s studies and generate the clinical data needed for regulatory progress.

  • Diagnostic collaboratorssecondary

    Partners such as Foresight Diagnostics that provide MRD testing to identify eligible patients and support trial design.

  • Regional development partnerssecondary

    Entities in greater China, Taiwan, South Korea and Singapore that hold rights to develop and commercialize licensed products in those territories.

Allogene is headquartered in the United States and conducts most of its development and corporate activity there,...

  • •United States is the main operating base for R&D and corporate functions
  • •Clinical development is centered in U.S. oncology and autoimmune programs
  • •Greater China, Taiwan, South Korea and Singapore are covered by a licensing territory
  • •Canada and Australia are being added for ALPHA3 trial expansion
  • •EU and UK development may be supported through the Foresight collaboration
  • •International execution matters because approvals and trial logistics differ by region

Allogene’s strategy is to prove that allogeneic, off-the-shelf CAR T can be safer, more scalable, and more practical...

01
Generate decisive clinical data in 2026short-term

The company needs readouts that demonstrate biologic activity, safety, and feasibility of standardized allogeneic CAR T therapy.

02
Advance cema-cel in LBCLmedium-term

Large B-cell lymphoma is the most advanced and commercially visible oncology opportunity in the pipeline.

03
Build a scalable autoimmune franchisemedium-term

Autoimmune disease could broaden the addressable market and diversify the company beyond oncology.

04
Reduce platform and partner dependency riskshort-term

The company relies on external technologies and collaborators for gene editing, diagnostics, and regional rights.

Allogene faces the classic risks of a clinical-stage biotech company: no approved products, ongoing losses, and a need...

critical

Clinical and regulatory failure of lead programs

ALPHA3, RESOLUTION, TRAVERSE and ALLO-329 are still in development, and novel cell therapies can fail on efficacy or safety.

Scope
Lead oncology and autoimmune assets
Materiality
high
high

Need for substantial additional financing

The company has recurring losses and must fund expensive clinical development before any product revenue exists.

Scope
Development programs and corporate operations
Materiality
high
high

Dependence on third-party licensors and collaborators

The company relies on Cellectis, Servier, Foresight Diagnostics and others for essential technology and trial support.

Scope
Gene editing, MRD testing, clinical execution
Materiality
high
high

Competition in CAR T and autoimmune cell therapy

Rivals may develop safer, more effective, or faster-to-market therapies and capture physician adoption first.

Scope
Oncology and autoimmune markets
Materiality
high
high

Manufacturing consistency and donor variability

Allogeneic products depend on healthy donor cells and reliable manufacturing processes to ensure consistent product quality.

Scope
Cell sourcing and production
Materiality
medium
Accrued research and development costs
Affects R&D expense and accrued liabilities
Collaboration revenue recognition
Affects reported revenue and comparability across periods
Stock-based compensation
Affects R&D and G&A expense
Impairment of long-lived assets
Can create non-cash charges in operating expense

Caribou Biosciences, Inc.

CRBU · Biological Products, (No Diagnostic Substances)

FATE THERAPEUTICS INC

FATE · Biological Products, (No Diagnostic Substances)

Lineage Cell Therapeutics, Inc.

LCTX · Biological Products, (No Diagnostic Substances)

Cullinan Therapeutics, Inc.

CGEM · Biological Products, (No Diagnostic Substances)

Adicet Bio, Inc.

ACET · Pharmaceutical Preparations

Lyell Immunopharma, Inc.

LYEL · Pharmaceutical Preparations

: 11/08/2026